Stocks to sell

“Meme stock mania” may have cooled down. But, over-hyped Genius Brands (NASDAQ:GNUS) stock continues to trade at an inflated valuation. The children’s entertainment company faces big hurdles. Not only does it face competition from the still-dominant media conglomerates. Big tech’s moves into streaming make it tough to compete as well. Yet, investors continue to overestimate
0 Comments
Colorado-based cryptocurrency miner Riot Blockchain (NASDAQ:RIOT) appointed board member Jason Les as its chief executive officer on Feb. 8. RIOT stock has more than doubled since the company appointed the Bitcoin (CCC:BTC-USD) expert to be its leader.  Source: Shutterstock While the stock pulled back in recent days, it’s still up more than 90% since that
0 Comments
With the shares of electric-vehicle stocks plunging, now is not a good time to buy Churchill Capital Corp IV (NYSE:CCIV) stock. Source: Pasuwan/ShutterStock.com On Feb. 22, confirming a long-running rumor, Churchill Capital, a SPAC, disclosed that it would merge with Lucid Motors. A luxury EV maker run by a former chief engineer of Tesla (NASDAQ:TSLA),
0 Comments
The previous lack of successful biofuels in developed nations and Gevo’s (NASDAQ:GEVO) high valuation are both factors that make me cautious on GEVO stock. The company develops low-carbon renewable fuels from plant sugars, but I’m not sure it’s a sustainable buy. Source: PhotographyByMK / Shutterstock.com Other worrisome trends for the stock include the apparent lack
0 Comments
At the beginning of December, TransEnterix (NYSEAMERICAN:TRXC) had a market capitalization of about $46 million. And with volatile drops between 20%-30% early morning of Feb. 23, TRXC stock’s inflated market cap is finally popping. But despite today’s carnage, it’s still up tenfold from December. Source: Shutterstock The obvious question is: what changed? And the answer
0 Comments
After Palantir (NYSE:PLTR) reported another quarterly loss on Feb. 16, I remain quite skeptical about the company’s medium-term outlook and its profitability. As a result, I continue to urge investors to sell PLTR stock. Source: Sundry Photography / Shutterstock.com Palantir reported a fourth-quarter earnings per share loss of 8 cents, versus analysts’ average estimate of
0 Comments
One aspect of our lives that was undergoing significant change before the novel coronavirus pandemic hit continues to evolve. Media stocks used to be television and radio station conglomerates that owned stations around the country. There were also cable companies that were running the parade of cable-infused services that were very popular a couple decades
0 Comments
Already trending higher thanks to improved U.S. pot legalization odds, Tilray (NASDAQ:TLRY) stock popped tremendously on Feb 10. After surging 40.8% on the previous day, the shares surged again, jumping from $42.35 to above $67, before ending the day at $63.91. Source: Jarretera / Shutterstock.com However, while the mania produced high profits for early buyers
0 Comments
Pot plays like Hexo (NYSE:HEXO) stock may have seen wild moves as of late, courtesy of Reddit traders. After the recent “blue wave” election results, things look more favorable for this space. U.S. legalization odds have improved. Both factors have some interested in this stock once again. But keep in mind that its many negatives
0 Comments
Artificial intelligence (AI) sounds vague, but the reality is it is just a computer that mimics human cognition. This allows it to be used in areas like robotics, machine learning, linguistics, and even psychology and philosophy! It’s also why AI is for more than a tool for just the tech sector. Source: Phonlamai Photo /
0 Comments
“Short-squeeze stocks” may be coming back to earth. But retail investors remain hot for “meme stocks.” And that’s the situation here with Sundial Growers (NASDAQ:SNDL) stock. With retail traders on Reddit’s WallStreetBets and other online platforms hyping it up, this “also ran” pot play has seen its shares take off significantly so far this month.
0 Comments
TransEnterix (NYSE:TRXC), which develops robots used in surgeries, has a chance to become a great company. Unfortunately, the medical-device maker’s relative weakness in the U.S., its tough competition and its low revenue prevent me from recommending TRXC stock at this time. Source: Phonlamai Photo / Shutterstock.com TransEnterix has developed a few revenue-generating niches that let
0 Comments